Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.49 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 5/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7796152 | 0.91 | NR1H4 (0.43) | NR1H4TNFRSF1ATHRBGAAALDH1A1 | |
| SCHEMBL7796619 | 0.90 | NR1H4 (0.45) | NR1H4TNFRSF1ATHRBGAAALDH1A1 | |
| SCHEMBL7786485 | 0.89 | NR1H4 (0.43) | NR1H4TNFRSF1ATHRBGAAALDH1A1 | |
| SCHEMBL7786480 | 0.89 | NR1H4 (0.44) | NR1H4TNFRSF1ATHRBGAAALDH1A1 | |
| SCHEMBL7786486 | 0.85 | THRB (0.45) | NR1H4TNFRSF1ATHRBALDH1A1TSHR | |
| SCHEMBL7786532 | 0.83 | THRB (0.61) | NR1H4THRBRXRARXRBRXRG | |
| SCHEMBL7796603 | 0.83 | GAA (0.45) | TNFRSF1ATHRBGAARXRARXRB | |
| SCHEMBL7786559 | 0.82 | THRB (0.46) | NR1H4THRBGAAALDH1A1TSHR | |
| SCHEMBL5740247 | 0.81 | TNFRSF1A (0.43) | TNFRSF1AALDH1A1TSHRTDP1DHFR | |
| SCHEMBL5736264 | 0.81 | FFAR1 (0.53) | NR1H4TNFRSF1AGAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| EP-0823435-B1 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL CO (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6242514-B1 | CYCLIC PHOSPHATE OR PHOSPHONATE; HEAT AND OXIDATION STABILIZER ESPECIALLY FOR OLEFIN POLYMERS AND ENGINEERING THERMOPLASTICS | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-5914361-A | IMPART HEAT STABILITY TO ORGANIC MATERIALS, INCLUDING POLYOLEFINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-06-22 | — | — | US | disclosed |
| US-5889095-A | OXYGEN AND HEAT RESISTANCE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0823435-A2 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | NR1H4 2618/4885TNFRSF1A 4433/4885THRB 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.